FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045292016> ?p ?o ?g. }

• W2045292016 endingPage "225" @default.
• W2045292016 startingPage "215" @default.
• W2045292016 abstract "Significant progress has been made in the understanding of the underlying cancer biology of castration‐resistant prostate cancer ( CRPC ) with the androgen receptor ( AR ) signalling pathway remaining implicated throughout the prostate cancer disease continuum. Reactivation of the AR signalling pathway is considered to be a key driver of CRPC progression and, as such, the AR is a logical target for therapy in CRPC . The objective of this review was to understand the importance of AR signalling in the treatment of patients with metastatic CRPC ( mCRPC ) and to discuss the clinical benefits associated with inhibition of the AR signalling pathway. A search was conducted to identify articles relating to the role of AR signalling in CRPC and therapies that inhibit the AR signalling pathway. Current understanding of prostate cancer has identified the AR signalling pathway as a logical target for the treatment of CRPC . Available therapies that inhibit the AR signalling pathway include AR blockers, androgen biosynthesis inhibitors, and AR signalling inhibitors. Enzalutamide, the first approved AR signalling inhibitor, has a novel mode of action targeting AR signalling at three key stages. The direct mode of action of enzalutamide has been shown to translate into clinical responses in patients with mCRPC . In conclusion, the targeting of the AR signalling pathway in patients with mCRPC results in numerous clinical benefits. As the number of treatment options increase, more trials evaluating the sequencing and combination of treatments are required. This review highlights the continued importance of targeting a key driver in the progression of CRPC , AR signalling, and the clinical benefits associated with inhibition of the AR signalling pathway in the treatment of patients with CRPC." @default.
• W2045292016 created "2016-06-24" @default.
• W2045292016 creator A5060302039 @default.
• W2045292016 creator A5075188714 @default.
• W2045292016 date "2015-06-06" @default.
• W2045292016 modified "2023-10-16" @default.
• W2045292016 title "Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer" @default.
• W2045292016 cites W1512914561 @default.
• W2045292016 cites W1904433804 @default.
• W2045292016 cites W1965002585 @default.
• W2045292016 cites W1975609403 @default.
• W2045292016 cites W1977645286 @default.
• W2045292016 cites W1980244461 @default.
• W2045292016 cites W1982445990 @default.
• W2045292016 cites W1996389184 @default.
• W2045292016 cites W2003955264 @default.
• W2045292016 cites W2005302422 @default.
• W2045292016 cites W2007144541 @default.
• W2045292016 cites W2014077960 @default.
• W2045292016 cites W2014751188 @default.
• W2045292016 cites W2022635468 @default.
• W2045292016 cites W2027602941 @default.
• W2045292016 cites W2054422997 @default.
• W2045292016 cites W2064293531 @default.
• W2045292016 cites W2066112327 @default.
• W2045292016 cites W2066723507 @default.
• W2045292016 cites W2077244514 @default.
• W2045292016 cites W2078699963 @default.
• W2045292016 cites W2080439368 @default.
• W2045292016 cites W2083926838 @default.
• W2045292016 cites W2084637523 @default.
• W2045292016 cites W2088318211 @default.
• W2045292016 cites W2097226696 @default.
• W2045292016 cites W2098706602 @default.
• W2045292016 cites W2104127658 @default.
• W2045292016 cites W2105129152 @default.
• W2045292016 cites W2108679313 @default.
• W2045292016 cites W2109783350 @default.
• W2045292016 cites W2110534364 @default.
• W2045292016 cites W2113747492 @default.
• W2045292016 cites W2115806147 @default.
• W2045292016 cites W2117296712 @default.
• W2045292016 cites W2118370975 @default.
• W2045292016 cites W2118564089 @default.
• W2045292016 cites W2119504728 @default.
• W2045292016 cites W2120292596 @default.
• W2045292016 cites W2121023961 @default.
• W2045292016 cites W2123526148 @default.
• W2045292016 cites W2123629153 @default.
• W2045292016 cites W2124792618 @default.
• W2045292016 cites W2125069527 @default.
• W2045292016 cites W2129750923 @default.
• W2045292016 cites W2131456094 @default.
• W2045292016 cites W2131868321 @default.
• W2045292016 cites W2131952914 @default.
• W2045292016 cites W2134988422 @default.
• W2045292016 cites W2137467802 @default.
• W2045292016 cites W2139677318 @default.
• W2045292016 cites W2144492823 @default.
• W2045292016 cites W2144908726 @default.
• W2045292016 cites W2146360937 @default.
• W2045292016 cites W2148643283 @default.
• W2045292016 cites W2153709799 @default.
• W2045292016 cites W2156923287 @default.
• W2045292016 cites W2157592394 @default.
• W2045292016 cites W2165782799 @default.
• W2045292016 cites W2166918329 @default.
• W2045292016 cites W2167547884 @default.
• W2045292016 cites W2168063883 @default.
• W2045292016 cites W2362782970 @default.
• W2045292016 cites W2464502417 @default.
• W2045292016 cites W2589166085 @default.
• W2045292016 cites W2591446263 @default.
• W2045292016 cites W2685622316 @default.
• W2045292016 cites W3140068379 @default.
• W2045292016 doi "https://doi.org/10.1111/bju.13123" @default.
• W2045292016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4744713" @default.
• W2045292016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25818596" @default.
• W2045292016 hasPublicationYear "2015" @default.
• W2045292016 type Work @default.
• W2045292016 sameAs 2045292016 @default.
• W2045292016 citedByCount "84" @default.
• W2045292016 countsByYear W20452920162015 @default.
• W2045292016 countsByYear W20452920162016 @default.
• W2045292016 countsByYear W20452920162017 @default.
• W2045292016 countsByYear W20452920162018 @default.
• W2045292016 countsByYear W20452920162019 @default.
• W2045292016 countsByYear W20452920162020 @default.
• W2045292016 countsByYear W20452920162021 @default.
• W2045292016 countsByYear W20452920162022 @default.
• W2045292016 countsByYear W20452920162023 @default.
• W2045292016 crossrefType "journal-article" @default.
• W2045292016 hasAuthorship W2045292016A5060302039 @default.
• W2045292016 hasAuthorship W2045292016A5075188714 @default.
• W2045292016 hasBestOaLocation W20452920162 @default.
• W2045292016 hasConcept C121608353 @default.
• W2045292016 hasConcept C126322002 @default.
• W2045292016 hasConcept C170493617 @default.

• next